Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Support holding ⢠Choppy breakout ⢠Profit-taking risk Support Level: $29.00-$29.20 Resistance Level: $32.50-$33.00 PLSE is technically constructive over the last month, with a choppy uptrend that held support and recently stalled near $32.50-$33.00, so bulls need to defend $29.00-$29.20 to keep the breakout attempt alive.
Sentiment & News
Key News Insights: ⢠Employee Grants ⢠Q2 Update ⢠Talent Retention Pulse Biosciences' latest updates are routine but constructive, combining inducement equity grants to new hires with a scheduled Q2 2026 earnings and business update on August 6.
AI Summary
PLSE has shifted from a broad platform story to a narrower, catalyst-driven bet on nPulse, and while momentum and insider buying support the setup, the stock now needs concrete clinical/progress proof because dilution risk and a sharp rerating leave limited room for disappointment.
Description
Pulse Biosciences, Inc. is a bioelectric medicine company that develops the CellFX System, a console-based platform that delivers nanosecond electrical pulses (Nano-Pulse Stimulation) to non-thermally remove targeted cells while sparing surrounding non-cellular tissue. The company was incorporated in 2014, changed its name from Electroblate, Inc. to Pulse Biosciences in December 2015, and is headquartered in Hayward, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 18 | Feb 25 | PLSE | Pulse Biosciences, Inc. | High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name. | Closed | -24.6% |
| Feb 11 | Feb 18 | PLSE | Pulse Biosciences, Inc. | FDA IDEs for NANOPULSEâAF and nPulse 360 EP plus strong firstâinâhuman ablation data (150 patients, presented 2026â02â05) triggered a ~75% threeâday jump and price ~55% above its 21âday SMA, making PLSE a highâvolatility clinicalâcatalyst momentum trade into the 2026â02â19 earnings update. | Closed | +0.8% |